This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2006 Jan;61(1):91.

doi: 10.1136/thx.2005.052233.

Complete response to erlotinib treatment in brain metastases from recurrent NSCLC

C S L Lai, C Boshoff, M Falzon, S M Lee

PMID: 16396957
PMCID: PMC2080696
DOI: 10.1136/thx.2005.052233

Case Reports

Complete response to erlotinib treatment in brain metastases from recurrent NSCLC

C S L Lai et al. Thorax. 2006 Jan.

. 2006 Jan;61(1):91.

doi: 10.1136/thx.2005.052233.

Authors

C S L Lai, C Boshoff, M Falzon, S M Lee

PMID: 16396957
PMCID: PMC2080696
DOI: 10.1136/thx.2005.052233

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: none.

Figures

None

See this image and copyright information in PMC

Similar articles

Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib.
Katz A, Zalewski P. Katz A, et al. Br J Cancer. 2003 Dec;89 Suppl 2(Suppl 2):S15-8. doi: 10.1038/sj.bjc.6601478. Br J Cancer. 2003. PMID: 14661048 Free PMC article. Review.
[Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months].
Mairovitz A, Staub E, Le Floch H, Rivière F, Bonnichon A, Margery J, Vaylet F. Mairovitz A, et al. Rev Pneumol Clin. 2009 Oct;65(5):318-21. doi: 10.1016/j.pneumo.2009.06.002. Epub 2009 Aug 29. Rev Pneumol Clin. 2009. PMID: 19878809 French.
High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
Hata A, Kaji R, Fujita S, Katakami N. Hata A, et al. J Thorac Oncol. 2011 Mar;6(3):653-4. doi: 10.1097/JTO.0b013e3181d899bb. J Thorac Oncol. 2011. PMID: 21317753 No abstract available.
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.
Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, Perng RP. Chiu CH, et al. Lung Cancer. 2005 Jan;47(1):129-38. doi: 10.1016/j.lungcan.2004.05.014. Lung Cancer. 2005. PMID: 15603863 Clinical Trial.
Brain metastasis responding to gefitinib alone.
Poon AN, Ho SS, Yeo W, Mok TS. Poon AN, et al. Oncology. 2004;67(2):174-8. doi: 10.1159/000081005. Oncology. 2004. PMID: 15539923 Review.

See all similar articles

Cited by

Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Kashima J, Okuma Y, Miwa M, Hosomi Y. Kashima J, et al. Med Oncol. 2016 Nov;33(11):129. doi: 10.1007/s12032-016-0843-8. Epub 2016 Oct 18. Med Oncol. 2016. PMID: 27757781 Clinical Trial.
Long-Term Survival of a Patient With Late-Stage Non-Small Cell Lung Cancer.
Allan-Blitz LT, Hashemi L. Allan-Blitz LT, et al. Fed Pract. 2016 Aug;33(Suppl 5):63S-65S. Fed Pract. 2016. PMID: 30766226 Free PMC article.
[Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases].
Xu J, Liu X, Yang S, Zhang X, Shi Y. Xu J, et al. Zhongguo Fei Ai Za Zhi. 2015 Sep 20;18(9):554-8. doi: 10.3779/j.issn.1009-3419.2015.09.05. Zhongguo Fei Ai Za Zhi. 2015. PMID: 26383979 Free PMC article. Chinese.
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
Lee SM, Lewanski CR, Counsell N, Ottensmeier C, Bates A, Patel N, Wadsworth C, Ngai Y, Hackshaw A, Faivre-Finn C. Lee SM, et al. J Natl Cancer Inst. 2014 Jul 16;106(7):dju151. doi: 10.1093/jnci/dju151. Print 2014 Jul. J Natl Cancer Inst. 2014. PMID: 25031274 Free PMC article. Clinical Trial.
Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases.
Xu JP, Liu XY, Yang S, Zhang CG, Wang L, Shi YK. Xu JP, et al. Thorac Cancer. 2016 Jul;7(4):437-41. doi: 10.1111/1759-7714.12351. Epub 2016 Apr 5. Thorac Cancer. 2016. PMID: 27385986 Free PMC article.

See all "Cited by" articles

References

1. Pao W, Miller V A. Epidermal growth factor receptor mutations, small‐molecule kinase inhibitors, and non‐small‐cell lung cancer: current knowledge and future directions. J Clin Oncol 2005232556–2568. - PubMed
1. Tsao M S, Sakurada A, Cutz J C.et al Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005353133–144. - PubMed
1. Cappuzzo F, Ardizzoni A, Soto‐Parra H.et al Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non‐small cell lung cancer (NSCLC). Lung Cancer 200341227–231. - PubMed
1. Fabian M A, Biggs W H, 3rd, Treiber D K.et al A small molecule‐kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 200523329–336. - PubMed
1. Shepherd F A, Rodrigues Pereira J, Ciuleanu T.et al Erlotinib in previously treated non‐small‐cell lung cancer. N Engl J Med 2005353123–132. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information